** Shares of Orthocell OCC.AX rise 11% to A$1.52, hitting their highest levels since Feb 20
** The biotech firm receives regulatory approval from Singapore's Health Sciences authority to start sales of its Striate+ product
** Striate+ is a dental guided bone regeneration product
** Says co working with Striate+ distribution partner BioHorizons to fast-track expansion to other regions including Brazil
** Stock up ~11.1% YTD, including current session's moves
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))